Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.

Matthew P GoetzMeena OkeraHans WildiersMario CamponeEva-Maria GrischkeLuis MansoValérie A M AndréNadia ChouakiBelén San AntonioMasakazu ToiGeorge W Sledge

Published in: Breast cancer research and treatment (2021)

ClinicalTrials.gov: NCT02107703 (first posted April 8, 2014) and NCT02246621 (first posted September 23, 2014).

Keyphrases

epidermal growth factor receptor
tyrosine kinase
advanced non small cell lung cancer
endothelial cells
induced pluripotent stem cells
middle aged
community dwelling
mesenchymal stem cells
bone marrow
young adults
open label
replacement therapy